Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia. (1st December 2020)

• Record Type: Journal Article
• Authors: Jaramillo, Adrian Christopher; Hubeek, Isabelle; Broekhuizen, Richard; Pastor-Anglada, Marçal; Kaspers, Gertjan J. L.; Jansen, Gerrit; Cloos, Jacqueline; Peters, Godefridus J.
• Is Part Of: Nucleosides, nucleotides & nucleic acids. Volume 39:Number 10/12(2020)
• Page Start: 1379
• Page End: 1388
• Publication Date: 2020-12-01
• Subjects: Acute myeloid leukemia (AML) -- acute lymphoblastic leukemia (ALL) -- human equilibrative nucleoside transporter-1 (hENT1) -- human concentrative nucleoside transporter-1 (hCNT1) -- deoxynucleoside analogs (NAs) -- cytarabine (Ara-C) -- bovine serum albumin (BSA) -- phosphate buffered saline (PBS); Nucleosides -- Periodicals; Nucleotides -- Periodicals; Nucleic acids -- Periodicals; 572.8
• DOI: 10.1080/15257770.2020.1746803
• Languages: English
• ISSNs: 1525-7770

Abstract

Abstract: Cellular uptake of clinically important deoxynucleoside analogs is mediated by nucleoside transporters including the human equilibrative nucleoside transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). These transporters are responsible for influx of cytarabine and reduced hENT1 expression is a major resistance mechanism in acute myeloid leukemia. We determined hENT1 and hCNT1 protein expression by immunocytochemistry in 50 diagnostic pediatric acute myeloid leukemia patient samples. All samples expressed hENT1 [9/43 (21%) low; 26/43 (60%) medium and 8/43 (19%) high] and hCNT1 [2/42 (5%) low; 35/42 (83%) medium and 5/42 (12%) high] at the cell membrane and cytoplasm. Statistical analysis showed a non-significant relationship between survival and transporter expression and in vitro drug sensitivity. In conclusion, the nucleoside transporters hENT1 and hCNT1 are broadly expressed in pediatric acute myeloid leukemia at diagnosis.